中证报中证网讯(记者傅苏颖)12月9日，中国证券报记者从泰德制药获悉，泰德制药自主研发的利多卡 因凝胶贴膏(商品名：得百宁)近日获得国家药监局批准上市，用于缓解糖尿病性周围神经病理性疼痛 (DPNP)治疗。 得百宁的成功上市，是泰德制药二十余年透皮制剂技术积累的又一硕果。自成立以来，泰德制药始终以 透皮制剂为核心赛道深耕，构建了国内领先的现代透皮技术平台与产品矩阵：2010年氟比洛芬凝胶贴膏 (得百安)上市，占据国内医院外用镇痛市场九成份额，年销突破30亿元；2018年得百宁获批填补带状疱 疹后遗神经痛外用治疗空白；2024年，阿尔茨海默病治疗贴剂苏乐达初上市即获广泛认可；2025年，妥 洛特罗贴剂(德瑞妥)成为平喘止咳良药；近期罗替高汀帕金森贴剂(罗菲定)获批进一步完善神经领域布 局，形成覆盖疼痛管理、中枢神经、代谢等多治疗领域的产品生态。按照规划，泰德制药预计2030年前 将推出14款经皮给药产品，持续完善"明星引领、梯队协同"的产品布局。 ...

Group 1 - Beijing Tide Pharmaceutical has launched its self-developed terbutaline patch (Derytuo) across major e-commerce platforms and offline pharmacies, marking it as the first domestically produced terbutaline patch in China [1] - The global transdermal drug delivery market is expanding at a compound annual growth rate (CAGR) of 5%, driven by an aging population and increasing chronic disease burden [1][3] Group 2 - The terbutaline patch utilizes innovative sustained-release technology to control the permeation rate, allowing for continuous absorption through the skin, thus overcoming traditional treatment limitations [2] - The patch is approved for patients aged 9 and above, with plans to extend its use to children under 9, potentially opening up the pediatric market [2] Group 3 - The global transdermal patch market is projected to grow from $7.88 billion in 2023 to $10.33 billion by 2029, with a CAGR of approximately 5% from 2024 to 2029 [3] - Beijing Tide has developed a comprehensive technology platform covering gel patches, hot melt adhesive patches, transdermal patches, and microneedle patches, establishing a fully controllable supply chain from raw materials to finished products [3][4] Group 4 - The company has successfully launched five patch products, including the first domestic non-steroidal anti-inflammatory gel patch, which has gained recognition among healthcare providers and patients [4] - With an annual production capacity of 330 million patches, Beijing Tide is accelerating the transformation of laboratory results into clinical value through partnerships with e-commerce platforms and educational content [4]